Overview

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Status:
Completed

Trial end date:
2017-03-09

Target enrollment:

Participant gender:

Summary

This multicenter, 2-stage, open-label, phase II trial aims to assess the efficacy and safety of dacomitinib in adult patients with recurrent Glioblastoma (GBM) with EGFR gene amplification and/or EGFRvIII mutation.

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Español de Investigación en Neurooncología

Collaborator:

Pfizer